| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Pathology, Microbiology and Immunology, University of South Carolina School of Medicine, Columbia, SC 29209
Vascular leak syndrome (VLS) is a life-threatening toxicity induced during IL-2 treatment of cancer patients. The mechanism of IL-2-induced VLS is still poorly understood. At present, there is no specific therapy for VLS. Previous studies from our laboratory demonstrated that hyaluronan (HA), a large glycosaminoglycan, abundant in the extracellular matrix and on the cell surface, caused a marked increase of IL-2-induced VLS in the lungs and liver of C57BL/6 mice. Conversely, blockade or knockout of its major receptor, CD44, resulted in a marked decrease of VLS, thereby suggesting a role for HA in VLS. In this study, we report a novel means to prevent IL-2-induced VLS by blocking endogenous HA with HA-specific binding peptide, Pep-1, a newly isolated peptide which specifically binds to soluble, cell-associated, and immobilized forms of HA. Our results demonstrated that blocking HA with Pep-1 dramatically inhibited IL-2-induced VLS in both normal mice as well as in mice bearing melanoma. Moreover, Pep-1 treatment maintained the effectiveness of IL-2 and prevented the metastasis of melanoma. IL-2-induced emigration of lymphocytes across the endothelium and cytotoxicity against tumor by lymphokine-activated killer cells were not affected by Pep-1. Instead, use of Pep-1 maintained endothelial integrity and reduced their apoptosis during IL-2-induced VLS. These data suggested that HA plays a critical role in regulating endothelial cell damage and induction of IL-2-mediated VLS. Also, blockade of HA using Pep-1 could constitute a novel therapeutic modality to prevent IL-2-mediated toxicity, thereby facilitating the effectiveness of high-dose IL-2 in the treatment of metastatic melanomas.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported by National Institutes of Health Grants R01 AI 053703, R01 DA 016545, R01 AI 058300, R01 HL 058641, and R01 ES 09098.
2 Address correspondence and reprint requests to Dr. Mitzi Nagarkatti, Department of Pathology, Microbiology, and Immunology, University of South Carolina School of Medicine, 6439 Garners Ferry Road, Columbia, SC 29209. E-mail address: mnagark{at}gw.med.sc.edu
3 Abbreviations used in this paper: VLS, vascular leak syndrome; HA, hyaluronan; LAK, lymphokine-activated killer cell; HABP, hyaluronan-binding protein; SC, scrambled control peptide.
This article has been cited by other articles:
|
|
 |
|
  P. L. Bollyky, B. A. Falk, R. P. Wu, J. H. Buckner, T. N. Wight, and G. T. Nepom Intact extracellular matrix and the maintenance of immune tolerance: high molecular weight hyaluronan promotes persistence of induced CD4+CD25+ regulatory T cells J. Leukoc. Biol., September 1, 2009; 86(3): 567 - 572. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Bollyky, B. A. Falk, S. A. Long, A. Preisinger, K. R. Braun, R. P. Wu, S. P. Evanko, J. H. Buckner, T. N. Wight, and G. T. Nepom CD44 Costimulation Promotes FoxP3+ Regulatory T Cell Persistence and Function via Production of IL-2, IL-10, and TGF-{beta} J. Immunol., August 15, 2009; 183(4): 2232 - 2241. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
